My dad has severe advanced stage Dementia. Will CBD oil help him at this point? He is now refusing to eat any solid food, but will accept most drinks.In addition, he has lost a great deal of weight even though they're giving him Mega Shakes containing a full meals worth of proteins, etc. He gets at least 4 of these a day..some which he refuses. Is his Dementia too far gone for CBD oils to help him?
Hemp rope was used in the age of sailing ships, though the rope had to be protected by tarring, since hemp rope has a propensity for breaking from rot, as the capillary effect of the rope-woven fibers tended to hold liquid at the interior, while seeming dry from the outside. Tarring was a labor-intensive process, and earned sailors the nickname "Jack Tar". Hemp rope was phased out when Manila, which does not require tarring, became widely available. Manila is sometimes referred to as Manila hemp, but is not related to hemp; it is abacá, a species of banana.
A population-based case-control study of 611 lung cancer patients revealed that chronic low Cannabis exposure was not associated with an increased risk of lung cancer or other upper aerodigestive tract cancers and found no positive associations with any cancer type (oral, pharyngeal, laryngeal, lung, or esophagus) when adjusting for several confounders, including cigarette smoking.
Although the environmental and biodiversity benefits of growing hemp have been greatly exaggerated in the popular press, C. sativa is nevertheless exceptionally suitable for organic agriculture, and is remarkably less “ecotoxic” in comparison to most other crops (Montford and Small 1999b). Figure 50 presents a comparison of the ecological friendliness of Cannabis crops (fiber, oilseed, and narcotics) and 21 of the world’s major crops, based on 26 criteria used by Montford and Small (1999a) to compare the ecological friendliness of crops.
Cannabinoids are a group of 21-carbon–containing terpenophenolic compounds produced uniquely by Cannabis species (e.g., Cannabis sativa L.).[1,2] These plant-derived compounds may be referred to as phytocannabinoids. Although delta-9-tetrahydrocannabinol (THC) is the primary psychoactive ingredient, other known compounds with biologic activity are cannabinol, cannabidiol (CBD), cannabichromene, cannabigerol, tetrahydrocannabivarin, and delta-8-THC. CBD, in particular, is thought to have significant analgesic, anti-inflammatory, and anxiolytic activity without the psychoactive effect (high) of delta-9-THC.
On the federal level, several bills currently before Congress seek to change the way the government treats CBD. One such bill, the Compassionate Access Act, would exclude CBD from the classification of “marijuana” and remove both from the DEA’s list of Schedule I controlled substances. Rescheduling CBD in such a way would make research and cultivation of CBD much easier.
Epidiolex is the first FDA-approved treatment in the U.S. that contains a purified drug substance derived from marijuana -- CBD -- and the first treatment for Dravet syndrome. In September 2018 the FDA rescheduled cannabidiol from a C-I controlled substance to a C-V controlled substance, meaning it has a proven medical use but a low risk of abuse. This change allows Epidiolex to be marketed in the U.S.
Topicals represent a newer emerging market in medical marijuana products geared toward health and beauty. Cannabinoids can be absorbed through the skin for certain therapeutic benefits without any psychoactivity. Additionally, the essential oils in hemp and cannabis provide many benefits for skin health. From moisturizers to shampoos and deodorants, medical cannabis products continue to diversify.
Cannabis, especially the cannabinoid CBD, has also demonstrated its abilities as a powerful anti-convulsant. This property is what accounts for cannabis’ ability to reduce the severity and frequency of seizures, especially for people with epilepsy. In the United States, epilepsy is the most widely adopted qualifying condition for medical cannabis use, especially for children.
Earliest reference to euphoric use of C. sativa appears to date to China of 5 millennia ago, but it was in India over the last millennium that drug consumption became more firmly entrenched than anywhere else in the world. Not surprisingly, the most highly domesticated drug strains were selected in India. While C. sativa has been used as a euphoriant in India, the Near East, parts of Africa, and other Old World areas for thousands of years, such use simply did not develop in temperate countries where hemp was raised. The use of C. sativa as a recreational inebriant in sophisticated, largely urban settings is substantially a 20th century phenomenon.
That leaves those touting CBD’s effectiveness pointing primarily to research in mice and petri dishes. There, CBD (sometimes combined with small amounts of THC) has shown promise for helping pain, neurological conditions like anxiety and PTSD, and the immune system—and therefore potentially arthritis, diabetes, multiple sclerosis, cancer, and more.
My mother has dementia/Alzheimers along with a broken knee that they will not repair do to her mental status. She is currently in a nursing home. I firmly believe her mental situation began with the over use of hydrocodone for over 30 years and was acerbated by the trauma of breaking and disconnecting her knee cap. Since weaning her off of her meds (still in progress) we have regained much of her consciousness. I want to try CBD to help in her recovery or to help slow down the disease. I cannot find a dosage recommendation plus the nursing home/doctor does not recommend it. I would need to give it to her when I am there visiting (about 3 - 4 times per week). Is there a recommended dosage for dementia/Alzheimers?
Jump up ^ Fusar-Poli, Paolo; Crippa, José A.; Bhattacharyya, Sagnik; Borgwardt, Stefan J.; Allen, Paul; Martin-Santos, Rocio; Seal, Marc; Surguladze, Simon A.; O'Carrol, Colin; Atakan, Zerrin; Zuardi, Antonio W.; McGuire, Philip K. (2009). "Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing". Archives of General Psychiatry. 66 (1): 95–105. doi:10.1001/archgenpsychiatry.2008.519. PMID 19124693.
The effects of delta-9-THC and a synthetic agonist of the CB2 receptor were investigated in HCC. Both agents reduced the viability of HCC cells in vitro and demonstrated antitumor effects in HCC subcutaneous xenografts in nude mice. The investigations documented that the anti-HCC effects are mediated by way of the CB2 receptor. Similar to findings in glioma cells, the cannabinoids were shown to trigger cell death through stimulation of an endoplasmic reticulum stress pathway that activates autophagy and promotes apoptosis. Other investigations have confirmed that CB1 and CB2 receptors may be potential targets in non-small cell lung carcinoma  and breast cancer.
Another study examined the effects of a plant extract with controlled cannabinoid content in an oromucosal spray. In a multicenter, double-blind, placebo-controlled study, the THC:CBD nabiximols extract and THC extract alone were compared in the analgesic management of patients with advanced cancer and with moderate-to-severe cancer-related pain. Patients were assigned to one of three treatment groups: THC:CBD extract, THC extract, or placebo. The researchers concluded that the THC:CBD extract was efficacious for pain relief in advanced cancer patients whose pain was not fully relieved by strong opioids. In a randomized, placebo-controlled, graded-dose trial, opioid-treated cancer patients with poorly controlled chronic pain demonstrated significantly better control of pain and sleep disruption with THC:CBD oromucosal spray at lower doses (1–4 and 6–10 sprays/day), compared with placebo. Adverse events were dose related, with only the high-dose group (11–16 sprays/day) comparing unfavorably with the placebo arm. These studies provide promising evidence of an adjuvant analgesic effect of THC:CBD in this opioid-refractory patient population and may provide an opportunity to address this significant clinical challenge. An open-label extension study of 43 patients who had participated in the randomized trial found that some patients continued to obtain relief of their cancer-related pain with long-term use of the THC:CBD oromucosal spray without increasing their dose of the spray or the dose of their other analgesics.
Recent European Commission proposals to change its subsidy regime for hemp contained the following negative evaluation of hemp seed: “The use of hemp seed ... would, however, even in the absence of THC, contribute towards making the narcotic use of cannabis acceptable... In this light, subsidy will be denied producers who are growing grain for use in human nutrition and cosmetics.”
"The data supporting efficacy and dosing are specific to one product: Epidiolex," Bonn-Miller says. "That's not necessarily translatable to 'Joe Bob's CBD Blend.'" A CBD extract you buy online or in a dispensary will almost certainly have less CBD in it, he explains, and will contain other cannabinoids—meaning that it will work differently and will need to be dosed differently. "This is not to say that 'Joe Bob's CBD Blend' definitely isn't going to be effective for pediatric epilepsy, but it means that we need to study it before we know."
In the United States, over three million people suffer from epilepsy – 470,000 of those people are children. Epilepsy is a disorder of the brain that causes seizures – of which there are over thirty different kinds, ranging from mild and infrequent to life-threatening. Not surprisingly, people with epilepsy face significant challenges – from the cost of healthcare to work limitations and social isolation.
This may be a good place to point out that not all CBD products are created equal. The industry is still largely unregulated, and the quality and quantity of CBD in a given product will vary wildly. Third party testing definitely helps to monitor companies’ claims, but it’s still up to you as the consumer to do your homework on the best CBD products.
An observational study assessed the effectiveness of nabilone in advanced cancer patients who were experiencing pain and other symptoms (anorexia, depression, and anxiety). The researchers reported that patients who used nabilone experienced improved management of pain, nausea, anxiety, and distress when compared with untreated patients. Nabilone was also associated with a decreased use of opioids, nonsteroidal anti-inflammatory drugs, tricyclic antidepressants, gabapentin, dexamethasone, metoclopramide, and ondansetron.
The US Drug Enforcement Administration’s online criminal justice statistics for 2000 (cscmosaic.albany.edu/sourcebook/1995/pdf/t440.pdf) shows the following seizures and eradication of plants of C. sativa: 40,929 outdoor plots (2,597,796 plants), 139,580,728 ditchweed (ruderal plants), 2,361 indoor operations (217,105 plants), for a grand total of 2,814, 903 plants destroyed. Impressively, the species was grown in all 50 states (including outdoor seizures in every state except Wyoming)! It is of course impossible to know exactly how much marijuana is cultivated in the United States, and perhaps only 10% to 20% of the amount grown is seized. The profitability of the illegal crop is indicated by a comparison of the cost of a bushel of corn (roughly $2.50) and a bushel of manicured marijuana (about $70,000; it has been suggested that prices range from $500 a pound, for low-quality marijuana, to more than $5,000 a pound for “boutique” strains like “Northern Lights” and “Afghan Kush”). According to a National Organization for the Reform of Marijuana Laws (NORML) (mir.drugtext.org/marijuananews/marijuana_ranks_fourth_largest_c.htm) marijuana is at least the fourth most valuable crop in America, outranked only by corn, soybeans, and hay. It was estimated that 8.7 million marijuana plants were harvested in 1997, worth $15.1 billion to growers and $25.2 billion on the retail market (the wholesale value was used to compare marijuana to other cash crops). Marijuana was judged to be the largest revenue producing crop in Alabama, California, Colorado, Hawaii, Kentucky, Maine, Rhode Island, Tennessee, Virginia, and West Virginia, and one of the top five cash crops in 29 other states.
Mike, what kind of breast cancer (invasive ductal, I presume)? How many of her lymph nodes were positive? How big was the primary tumor? Reason I ask is that in women with Stage I or IIA tumors that are estrogen-and progesterone-receptor-positive and HER2-negative (ER+/PR+/HER2-) with three or fewer positive lymph nodes, there is a genomic assay test on a sample of the tumor, called OncotypeDX, that will tell doctors whether chemo is necessary or would even work at all. Medicare covers that test 100%.That type of breast cancer mentioned above, which I had as Stage IA, is treated in postmenopausal women with anti-estrogen drugs called aromatase inhibitors(aka AIs: anastrazole, letrozole, or exemestane)which have as a side effect joint pain. CBD oil is effective for this joint pain it is not, I repeat, NOT a substitute for chemo, radiation or these anti-estrogen drugs.So don’t assume your mom’s cancer will require chemo; but if it does, CBD helps with those side effects as well. If she lives in a state where medical marijuana is legal, there are doctors who sub-specialize in certifying applications for a medical marijuana card, and in the interim before the card is issued can advise as to the appropriate dose of CBD oil (legal and over-the-counter in all 50 states). Some (though not most) medical oncologists will certify their own patients’ medical marijuana card applications so she need not seek out another doctor; and will advise the appropriate dose for her symptoms. Once she gets her card, the “budtenders” in the licensed dispensaries can advise her as to the right CBD product (with or without THC), strength, and dosage. If she lives in a state where recreational weed is legal, the “budtenders” in the marijuana shops can steer her to the right strength of CBD oil and the right dosage.
Medical marijuana refers to the use of the Cannabis plant as a physician-recommended herbal therapy as well as synthetic THC and cannabinoids. So far, the medical use of cannabis is legal only in a limited number of territories, including Canada, Belgium, Australia, the Netherlands, Spain, and many U.S. states. This usage generally requires a prescription, and distribution is usually done within a framework defined by local laws. There is evidence supporting the use of cannabis or its derivatives in the treatment of chemotherapy-induced nausea and vomiting, neuropathic pain, and multiple sclerosis. Lower levels of evidence support its use for AIDS wasting syndrome, epilepsy, rheumatoid arthritis, and glaucoma.
"A CBD company may create a CBD oil, test it, and use the test results to create their label," Bonn-Miller says. "The problem is if they never test their product again, or they test it once a year, you have no idea whether each batch is the same as the first one that they used to create the label. The vast majority of companies are not using manufacturing standards that assure product consistency over time. Companies should be testing every batch they make and tossing batches that don't fall within the specs of their label."
Hemp seeds contain virtually no THC, but THC contamination results from contact of the seeds with the resin secreted by the epidermal glands on the leaves and floral parts, and also by the failure to sift away all of the bracts (which have the highest concentration of THC of any parts of the plant) that cover the seeds. This results in small levels of THC appearing in hempseed oil and foods made with the seeds. Although most of the western hemp-growing world uses 0.3% THC as a maximum concentration for authorized cultivation of hemp plants, regulations in various countries allow only a much lower level of THC in human food products manufactured from the seeds. Currently, up to 10 ppm THC is permitted in seeds and oil products used for food purposes in Canada. In Germany, more stringent limits were set for food in 2000: 5 ppm in food oil, 0.005 ppm in beverages, and 0.15 ppm in all other foods. The US Drug Enforcement Administration published new regulations on hemp in the Federal Register on October 9th 2001 that in effect 4 months later would ban the food use of hemp in the US because any amount of THC would be unacceptable in foods (follow links at www.hempreport.com/). These proposals are currently being challenged by the hemp industry. Limits have been set because of concerns about possible toxicity and interference with drug tests (Grotenhermen et al. 1998). An extensive analysis of literature dealing with the toxicity of hemp is in Orr and Starodub (1999; see Geiwitz 2001 for an analysis). Because hemp food products are considered to have great economic potential, there is considerable pressure on the hemp industry in North America to reduce THC levels.
As marijuana is legalized in more and more states, the wellness world has whipped itself into a frenzy over a non-intoxicating cannabis derivative called cannabidiol. CBD products can be found on the internet and in health-food stores, wellness catalogs and even bookstores. (A bookstore in downtown Boulder, Colorado, displays a case of CBD products between the cash register and the stacks of new releases.) Celebrities like Gwyneth Paltrow, disgraced cyclist1 Floyd Landis and former Denver Broncos quarterback Jake Plummer are all touting CBD products, and according to Bon Appétit, CBD-infused lattes have become “the wellness world’s new favorite drink.”
A panellized system of hemp-lime panels for use in building construction is currently under test in a European Union-funded research collaboration led by the University of Bath. The panels are being designed to assure high-quality construction, rapid on-site erection, optimal hygrothermal performance from day one, and energy- and resource-efficient buildings. The 36-month-long work programme aims to refine product and manufacturing protocols, produce data for certification and marketing, warranty, insurance cover, and availability of finance. It also includes the development of markets in Britain, France, and Spain.